Skip to main content

Abvc Biopharma, Inc.

ABVC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001173313

No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.

Other share classesECOC

Q1 2026 vs. Q4 2025

How the institutions holding Abvc Biopharma, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of ABVC: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders141130
Shares854.9K287.9K816.5K+249.6K (+44.0%)
Value$1.82M$613.3K$792.1K−$415.6K (−34.4%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Abvc Biopharma, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ABVC in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Capital Management LLC190,574$184.9K0.00%
Vanguard Fiduciary Trust Co97,363$94.4K0.00%
Two Sigma Securities, LLC21,023$20.4K0.00%
Dimensional Fund Advisors LP12,227$11.9K0.00%
Squarepoint Ops LLC10,547$10.2K0.00%
Royal Bank of Canada17$00.00%

Sold out (6)

Institutions that held Abvc Biopharma, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of ABVC in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Citadel Advisors LLC55,543$118.3K
XTX Topco Ltd11,261$24.0K
Jane Street Group, LLC10,867$23.1K
Morgan Stanley5,175$11.0K
Simplex Trading, LLC196$417
Bank of America Corp189$402

Not filed for Q1 2026 yet (1)

Institutions that held Abvc Biopharma, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ABVC in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc287,937$613.3K